Summary: “We found a statistically very persuasive difference between MDMA and placebo,” explains Berra Yazar-Klosinski, Ph.D., of MAPS and MAPS Public Benefit Corporation (MAPS PBC) on ABC News Live.
Watch Maggie Rulli of ABC News dive into the results of MAPS’ first Phase 3 clinical trial of MDMA-assisted therapy for PTSD, examine the personal experience of a study participant in the UK, and illustrate the “potentially groundbreaking medical benefits of MDMA” when combined with therapy.
Originally appearing here.
